JPET

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rosen, M. I.
Right arrow Articles by Kosten, T. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rosen, M. I.
Right arrow Articles by Kosten, T. R.

Effect of clonidine pretreatment on naloxone-precipitated opiate withdrawal

MI Rosen, TJ McMahon, FA Hameedi, HR Pearsall, SW Woods, MJ Kreek and TR Kosten

Connecticut Mental Health Center, New Haven, USA.

The purpose of this pilot study was to validate a methodology for testing the opioid withdrawal-attenuating effects of new medications using clonidine as a positive control. Seven heroin-dependent subjects stabilized on levorphanol received naloxone challenge tests on 4 consecutive days in a 2 x 2 design with placebo or clonidine (0.4-0.5 mg) pretreatment, followed by 0.2 or 0.4 mg of i.v. naloxone. The change in the area-under-the-curve from the preclonidine base line for various measures of withdrawal was analyzed in a two-factor (naloxone dose and clonidine condition) analysis of variance. Clonidine significantly (P < .05) attenuated systolic and diastolic blood pressure, pulse, lacrimation, nasal congestion and plasma cortisol, but not subject-rated withdrawal severity. There was a robust dose- dependent adrenocorticotropic hormone response to naloxone that was not changed by clonidine pretreatment. The consistency between these results and prior studies of clonidine's antiwithdrawal efficacy suggests the validity of the methodology for testing medications to treat opiate withdrawal. Studies with larger samples are needed to refine this methodology.

Volume 276, Issue 3, pp. 1128-1135, 03/01/1996
Copyright © 1996 by American Society for Pharmacology and Experimental Therapeutics




This article has been cited by other articles:


Home page
 Am. J. Pathol.Home page
X. Wang, S. D. Douglas, J.-S. Peng, D.-J. Zhou, Q. Wan, and W.-Z. Ho
An in Vitro Model of Morphine Withdrawal Manifests the Enhancing Effect on Human Immunodeficiency Virus Infection of Human T Lymphocytes through the Induction of Substance P
Am. J. Pathol., November 1, 2006; 169(5): 1663 - 1670.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
C.-Q. Wang, Y. Li, S. D. Douglas, X. Wang, D. S. Metzger, T. Zhang, and W.-Z. Ho
Morphine Withdrawal Enhances Hepatitis C Virus Replicon Expression
Am. J. Pathol., November 1, 2005; 167(5): 1333 - 1340.
[Abstract] [Full Text] [PDF]

Home page
 ANN INTERN MEDHome page
P. G. O'Connor and D. A. Fiellin
Pharmacologic Treatment of Heroin-Dependent Patients
Ann Intern Med, July 4, 2000; 133(1): 40 - 54.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 1996 by the American Society for Pharmacology and Experimental Therapeutics.